Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which …

Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …

In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly
improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive …

Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling …

Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer management.
However, molecular determinants of response to ICIs remain incompletely understood …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-
small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on …

Purpose: To investigate the impact of programmed death-ligand 1 (PD-L1) expression,
oncogenic mutations, and clinical characteristics on survival after treatment with anti-PD …

Despite advances made during the last two decades, lung cancer remains the leading
cause of cancer-related death worldwide. Recently, immune checkpoint inhibitors (ICIs) …

Background Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some
patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying …